Evidence map›Paper›PMID 38113099›Full record

ArticleJMIR formative research2023

Patient Portal Use and Risk of Readmissions in Decompensated Cirrhosis: Retrospective Study.

Jeremy Louissaint, Jeffrey Gibbs, Abhishek Shenoy, Shirley Cohen-Mekelburg, Anna Lok, Elliot Tapper

Open access · goldAbstract read
In one paragraph

Article in JMIR formative research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jeremy LouissaintDivision of Digestive and Liver Diseases, University of Texas Southwestern, Dallas, TX, United States.ORCID https://orcid.org/0000-0003-1154-1825
Jeffrey GibbsDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.ORCID https://orcid.org/0000-0001-5722-584X
Abhishek ShenoyDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.ORCID https://orcid.org/0000-0002-9467-2873
Shirley Cohen-MekelburgDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.ORCID https://orcid.org/0000-0001-5058-5527
Anna LokDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.ORCID https://orcid.org/0000-0002-5811-6845
Elliot TapperDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.ORCID https://orcid.org/0000-0002-0839-1515
University of Michigan · USThe University of Texas Southwestern Medical Center · US

Funding

Training Program in Gastrointestinal EpidemiologyT32DK062708 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Peter D.R. Higgins, Elliot Tapper · 2003 to 2026
$3.9M
Optimizing Measures for Clinical Trials in Covert Hepatic EncephalopathyK23DK117055 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TAPPER, ELLIOT · 2019 to 2022
$776k
NIDDK NIH HHS K23 DK117055NIDDK NIH HHS T32 DK062708
6 · The paper itself

Abstract

backgroundPatient portals are a common electronic medical record tool that allow for the asynchronous exchange of health information between patients and their health care teams. Patients can leverage patient portals to perform tasks such as viewing test results, reviewing clinical notes, and messaging their health care team. The impact of patient portal use on clinical outcomes in cirrhosis is unknown.

objectiveIn this study, we evaluated the relationship between patient portal use patterns and readmissions in cirrhosis.

methodsWe identified 131 patients with decompensated cirrhosis with an index cirrhosis-related admission between May 1, 2018, and May 1, 2019. We then examined patient portal enrollment and use data during the 6-month period preceding the study period. Portal functions evaluated included sending a message, reading a message, and reading a test result. Use was categorized as active (sending a message) and passive (reading a message or test result) and was further stratified as no, moderate, or frequent use based on the frequency of portal function use compared to the mean. The primary outcomes were 90-day and overall readmissions, adjusted for age, model for end-stage liver disease-sodium, alcohol-related cirrhosis etiology, ascites, and hepatic encephalopathy. Portal functions assessed included sending a message, reading a message, and reading a result; the total number of times a portal function was performed was divided by the number of months the patient was enrolled in the patient portal during the 6-month period.

resultsThe study population was 50.4% (66/131) female, with a mean age of 58 years. Enrollment in the patient portal was 63.4% (83/131), and there was no significant difference in enrollment based on clinical or demographic characteristics. For the entire cohort, 14.5% (19/131) and 22.1% (29/131) of patients were moderate and frequent active users, respectively. Of those enrolled in the patient portal, 97.6% (81/83) of patients were moderate or frequent passive users for both reading a message and reading a test result. Moderate active users had less 90-day readmissions (odds ratio 0.77, 95% CI 0.60-1.00) and overall readmissions (subdistribution hazard ratio 0.42, 95% CI 0.21-0.84), compared to nonactive users. There was no relationship between readmissions and passive use.

conclusionsPassive use of the patient portal is very high but is not associated with the risk of readmissions in people with decompensated cirrhosis. However, moderately active use of the patient portal is associated with a reduced risk of readmissions. Further work is needed to identify possible confounders and refine key use behaviors that may be protective with regard to the risk of readmission in this population.

Indexed as

cirrhosispatient portalreadmissionstelehealthtelemedicine

Identifiers

PMID38113099
PMCPMC10762613
OpenAlexW4389948948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.